Vectormune ND

Country: European Union

Language: Spanish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

virus de herpes de pavo recombinante vivo asociado a células (rHVT / ND) que expresa la proteína de fusión de la cepa lentogénica del virus de las enfermedades de Newcastle D-26

Available from:

CEVA-Phylaxia Co. Ltd.

ATC code:

QI01AD

INN (International Name):

Newcastle disease and Marek’s disease vaccine (live recombinant)

Therapeutic group:

Chicken; Embryonated eggs

Therapeutic area:

Immunologicals para aves, las vacunas virales

Therapeutic indications:

Para la inmunización activa de 18 días de edad, los huevos embrionados de pollo o los pollitos de un día para reducir la mortalidad y los signos clínicos causados por la enfermedad de Newcastle virus y reducir la tasa de mortalidad, signos clínicos y las lesiones causadas por la enfermedad de Marek virus con un fenotipo "virulenta".

Product summary:

Revision: 7

Authorization status:

Autorizado

Authorization date:

2015-09-08

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
La información actualizada sobre este medicamento veterinario está
disponible en el sitio web de
información sobre medicamentos veterinarios.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
La información actualizada sobre este medicamento veterinario está
disponible en el sitio web de
información sobre medicamentos veterinarios.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-02-2024
Public Assessment Report Public Assessment Report Bulgarian 10-04-2018
Patient Information leaflet Patient Information leaflet Czech 15-02-2024
Public Assessment Report Public Assessment Report Czech 10-04-2018
Patient Information leaflet Patient Information leaflet Danish 15-02-2024
Public Assessment Report Public Assessment Report Danish 10-04-2018
Patient Information leaflet Patient Information leaflet German 15-02-2024
Public Assessment Report Public Assessment Report German 10-04-2018
Patient Information leaflet Patient Information leaflet Estonian 15-02-2024
Public Assessment Report Public Assessment Report Estonian 10-04-2018
Patient Information leaflet Patient Information leaflet Greek 15-02-2024
Public Assessment Report Public Assessment Report Greek 10-04-2018
Patient Information leaflet Patient Information leaflet English 15-02-2024
Public Assessment Report Public Assessment Report English 10-04-2018
Patient Information leaflet Patient Information leaflet French 15-02-2024
Public Assessment Report Public Assessment Report French 10-04-2018
Patient Information leaflet Patient Information leaflet Italian 15-02-2024
Public Assessment Report Public Assessment Report Italian 10-04-2018
Patient Information leaflet Patient Information leaflet Latvian 15-02-2024
Public Assessment Report Public Assessment Report Latvian 10-04-2018
Patient Information leaflet Patient Information leaflet Lithuanian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-02-2024
Public Assessment Report Public Assessment Report Lithuanian 10-04-2018
Patient Information leaflet Patient Information leaflet Hungarian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 15-02-2024
Public Assessment Report Public Assessment Report Hungarian 10-04-2018
Patient Information leaflet Patient Information leaflet Maltese 15-02-2024
Public Assessment Report Public Assessment Report Maltese 10-04-2018
Patient Information leaflet Patient Information leaflet Dutch 15-02-2024
Public Assessment Report Public Assessment Report Dutch 10-04-2018
Patient Information leaflet Patient Information leaflet Polish 15-02-2024
Public Assessment Report Public Assessment Report Polish 10-04-2018
Patient Information leaflet Patient Information leaflet Portuguese 15-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 15-02-2024
Public Assessment Report Public Assessment Report Portuguese 10-04-2018
Patient Information leaflet Patient Information leaflet Romanian 15-02-2024
Public Assessment Report Public Assessment Report Romanian 10-04-2018
Patient Information leaflet Patient Information leaflet Slovak 15-02-2024
Public Assessment Report Public Assessment Report Slovak 10-04-2018
Patient Information leaflet Patient Information leaflet Slovenian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 15-02-2024
Public Assessment Report Public Assessment Report Slovenian 10-04-2018
Patient Information leaflet Patient Information leaflet Finnish 15-02-2024
Public Assessment Report Public Assessment Report Finnish 10-04-2018
Patient Information leaflet Patient Information leaflet Swedish 15-02-2024
Public Assessment Report Public Assessment Report Swedish 10-04-2018
Patient Information leaflet Patient Information leaflet Norwegian 15-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 15-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 15-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 15-02-2024
Patient Information leaflet Patient Information leaflet Croatian 15-02-2024
Public Assessment Report Public Assessment Report Croatian 10-04-2018

View documents history